BCc1 exhibits a dual regulatory effect—upregulating tumor-suppressive Beclin-1 while downregulating pro-survival ATG-4B, ATG-7, and mTOR—in a manner dependent on dose and administration route. Here, ATG4B is linked to neoplasm.